Duloxetine Capsule, Delayed Release
Product Images NDC 50090-5940

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 50090-5940). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Duloxetine Fig1)

A Kaplan-Meier curve chart comparing the proportion of patients with relapse over time in days from randomization. The graph shows two treatment groups: Placebo and Duloxetine, with the y-axis representing the proportion of patients with relapse and the x-axis representing time up to 200 days.*

FDA Label Image

Figure10 (Duloxetine Fig10)

A line graph comparing the percentage of patients improved based on percent improvement in pain from baseline between placebo and Duloxetine 60/120 mg once daily. The x-axis represents percent improvement in pain from baseline, and the y-axis shows the percentage of patients improved. Two lines depict patient improvement trends for placebo and Duloxetine treatment groups.*

FDA Label Image

Figure2 (Duloxetine Fig2)

A line graph comparing the proportion of patients with relapse over time from randomization, shown in days, between two treatments: placebo and duloxetine. The y-axis represents the proportion of patients with relapse, ranging from 0 to 1. The x-axis represents time in days, up to about 275 days. The graph shows that patients treated with duloxetine have a lower relapse proportion compared to placebo over the observed period.*

FDA Label Image

Figure3 (Duloxetine Fig3)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo. The graph compares the efficacy of these treatments in pain improvement over various thresholds.*

FDA Label Image

Figure4 (Duloxetine Fig4)

A line graph comparing percentage improvement in pain from baseline with the percentage of patients improved. It shows three groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, and Placebo, with patient improvement percentage decreasing as percent improvement in pain increases from 0 to 100%.*

FDA Label Image

Figure5 (Duloxetine Fig5)

A line graph illustrating the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo groups. The graph shows comparative effectiveness of two dosing regimens of Duloxetine and placebo on pain improvement.*

FDA Label Image

Figure6 (Duloxetine Fig6)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine at 120 mg, 60 mg, 20 mg once daily, and placebo. The y-axis represents the percentage of patients improved, and the x-axis shows percent improvement in pain from baseline, ranging from greater than 0 to 100.*

FDA Label Image

Figure8 (Duloxetine Fig8)

A line graph comparing the percentage of patients improved in pain from baseline between a placebo group and a Duloxetine 60/120 mg once daily group. The x-axis represents percent improvement in pain from baseline, and the y-axis shows the percentage of patients improved. Two plotted lines show patient improvement percentages across different pain improvement thresholds.*

FDA Label Image

Figure9 (Duloxetine Fig9)

A line graph comparing percentage of patients improved between Duloxetine 60 mg once daily and placebo. The x-axis represents percent improvement in pain from baseline measured by BOCF, and the y-axis shows the percentage of patients improved. Duloxetine shows a higher percentage of patient improvement than placebo across most levels of pain improvement.*

FDA Label Image

Structure (Duloxetine Structure)

Chemical structure of Duloxetine depicted as a molecular diagram showing its atomic connections, including a naphthyl group, thiophene ring, and amine hydrochloride moiety, consistent with the active ingredient Duloxetine.*

FDA Label Image

Label Image (Lbl500905940)

Label for Duloxetine delayed release capsules, 60 mg strength, manufactured by A-S Medication Solutions. The label indicates the product number, lot number, and that each capsule contains enteric-coated pellets of duloxetine hydrochloride equivalent to 60 mg duloxetine. The package contains 30 capsules and includes storage instructions to keep at 77 degrees Fahrenheit.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.